Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-3424 in Advanced Solid Tumors
NCT06239155Phase 2Active, not recruiting
- Sponsor
- Ascentawits Pharmaceuticals Ltd.
- Start
- Sep 2019
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of odafosfamide in solid tumor (advanced stage), hepatocellular carcinoma (HCC), sponsored by Ascentawits Pharmaceuticals Ltd.. Started Sep 2019; status: active, not recruiting.
02
Drugs
odafosfamide
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06239155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239155.